GentiBio
Andy is Co-founder and Chief Technology Officer of GentiBio. Prior to joining GentiBio, Dr. Walker was Chief Executive Officer of Jewel Biotherapeutics and formerly Senior Vice President of Technical Operations at Juno Therapeutics, as well as serving in multiple senior leadership roles at AGC Biologics. He is an experienced senior leader overseeing Process Development and GMP manufacturing of cellular therapeutics and protein biologics. Dr. Walker received his B.S. in Chemical Engineering from the University of Washington and his Ph.D. in Chemical engineering from the University of California, Berkeley.
This person is not in any teams
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.